Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Reverse the progression of Alzheimer’s disease through NanoERASERbased adult neuroregeneration

Neurodegeneration in Alzheimer’s disease outpaces the brain’s ability to regenerate neurons. Wang et al. develop a Nano-ERASER platform that delivers anti-PTBP1 antibodies into astrocytes, enabling proteasome-mediated PTBP1 degradation and activating neuronal reprogramming. This nanotechnology-based Trim-Away system induces functional neurogenesis in vitro, in human brain organoids, and in AD mouse brains, thereby improving learning and memory. The study introduces a regenerative therapeutic paradigm in which biomaterials and endogenous glia collaborate to rebuild neural circuits in Alzheimer’s disease.

Columbia engineers built a pigmentfree polymer coating filled with microscopic air pores; under Arizona desert sun, the coated surface stayed about 6°C below ambient air

As temperatures rise during hot weather, keeping buildings and other structures cool can require large amounts of energy. Air conditioners are a common way to deal with the heat, but they consume electricity and need access to cooling systems and, in some cases, coolants that can affect the environment.

ABB And NVIDIA’s 99% SimtoReal Accuracy Claim: What The Number Leaves Out

ABB and NVIDIA are embedding Omniverse simulation libraries into RobotStudio under the name HyperReality, claiming up to 99% sim-to-real accuracy, 80% faster setup, 40% lower costs, and 50% faster time-to-market. Foxconn is piloting the system for consumer electronics assembly. The number is real and independently attributable, but it describes one company’s controlled pilot, not a guarantee that transfers to messier industrial environments.

Sim-to-real accuracy just got its most specific headline number yet, and the company behind it has a real customer already running it. ABB is integrating NVIDIA’s Omniverse simulation libraries into its RobotStudio platform under the name HyperReality, targeting sim-to-real accuracy of up to 99%, according to a March 2026 report on the partnership. The companies also claim setup and commissioning time can drop by up to 80%, costs by up to 40%, and time-to-market by 50%, with a full release planned for the second half of 2026.

Unlike many simulation vendor claims that cite no production deployment, this one has a specific, named early adopter. Foxconn is already piloting HyperReality for consumer electronics assembly, training its robots on synthetic data across multiple production scenarios before deploying them to real lines, according to the same report. Foxconn’s Chief Digital Officer, Dr. Zhe Shi, said the level of accuracy and fidelity now possible in simulation and digital twins wasn’t achievable before this collaboration. That’s a meaningfully different evidentiary standard than an unverified sim-to-real accuracy claim sitting in a press release with no customer attached.

Deep brain stimulation shows potential to improve communication after traumatic brain injury

Deep brain stimulation, or DBS, may help improve speech and swallowing problems caused by traumatic brain injury (TBI), according to a new University of Pittsburgh School of Medicine study published in Nature Communications.

The proof-of-concept study found that low-frequency electrical stimulation of the motor thalamus, a deep brain region connected to the motor cortex, improved control of facial and tongue muscles involved in speaking and swallowing. The findings suggest that DBS may be able to strengthen remaining communication pathways between the brain and muscles after TBI, with the potential to improve and partially restore a person’s ability to communicate verbally.

The study, led by Elvira Pirondini, Ph.D., assistant professor of physical medicine and rehabilitation at Pitt’s Rehab Neural Engineering Laboratory, and Jorge A. Gonzalez-Martinez, M.D., Ph.D., professor of neurological surgery at Pitt, builds on the group’s previous work using neuromodulation to improve arm and hand movement after brain injury.

InPatient Multimodal Intensive Neurorehabilitation and Care Improve Motor and NonMotor Functions in the Moderately Advanced Stages of Parkinson’s Disease: A Retrospective Study in a U.S. Facility

Background: Previous studies, mostly performed in European centers, have shown that in-patient multimodal intensive rehabilitation treatments lasting for two to four weeks can improve both motor and non-motor symptoms of Parkinson’s disease (PD) with long-lasting effects. Here, we ascertain the effects of a similar in-patient program in a U.S. center with a retrospective study in a cohort of 153 patients in the moderately advanced stage of PD. Methods: We compared indices of motor and non-motor functions before and immediately after such treatment and investigated the possible differences between men and women. We used the available records of the Beck Depression Inventory, PDQ39, PD Sleep Scale, Timed Up and Go, Vocal Volume, Voice Handicap, and total UPDRS scores. Results: We found that at the end of treatment, which lasted an average of 14 days, all outcome measures significantly improved independently of sex. Conclusions: These results confirm the previous findings with a similar in-patient approach in European centers. They further suggest that this in-patient treatment is a care model that is feasible in U.S. centers and can provide a more immediate benefit to the motor function and quality of life of patients with moderately advanced PD.

Removing immune ‘brake’ improves CAR T-cell therapy for pediatric bone cancer

Scientists at St. Jude Children’s Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma. There is a great clinical need for new therapies for childhood osteosarcoma, for which there are very few effective treatments for relapsed disease. The approach improved the cells’ ability to control osteosarcoma growth and prevent metastasis to the lungs in preclinical models. The findings support the development of an early-phase clinical trial and were published today in Cell Reports Medicine.

Chimeric antigen receptor (CAR) T-cell therapy reprograms a patient’s own immune cells to recognize and attack cancer. The treatment has shown success in some relapsed childhood leukemias, but it has not worked as well against solid tumors, including osteosarcoma. One major reason is that the tumor microenvironment, the local area around the tumor, can suppress anticancer immune activity and cause CAR T cells to become less functional.

To overcome these barriers, the St. Jude group removed the gene for Regnase-1 (which normally acts as a “brake” on immune function) from CAR T cells, then tested the modified cells in mouse models of osteosarcoma.

Infrasound exposure is linked to aversive responding, negative appraisal, and elevated salivary cortisol in humans

:

Infrasound describes sound wave frequencies below 20 Hz, which are typically imperceptible to humans. Some animals perceive and demonstrate aversion to infrasound, raising concerns about its potential adverse effects as an anthropogenic pollutant. Recent research suggests humans may also respond to infrasound, despite being below the conventional limit of human hearing. This study explored the non-auditory impact of infrasound on human mood and stress responding.

/* */